CARDINAL is a global, multicenter, open-label, two-part Phase 1 clinical trial to evaluate the safety, pharmacokinetics (PK), and efficacy of TERN-701 in patients with relapsed/refractory CML with or ...

Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

Dr. Ruemu Birhiray explains chronic myeloid leukemia (CML), its treatment options, and what patients should know about this ...

In January 1995, at the age of 37, my life changed forever. As an active Army officer, husband, and father to a 5-year-old daughter, I was diagnosed with chronic myeloid leukemia (CML). The prognosis ...

Chronic lymphocytic leukemia (CLL) is a type of cancer that affects white blood cells (WBCs). Since these blood cells are part of the immune system, CLL affects the body’s ability to fight germs ...

The difference between hereditary (germline) and acquired (somatic) gene mutations in cancer can lead to much confusion. This is especially true if you’re hearing about genetic testing for a genetic ...

Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm characterized by CSF3R mutations. Here, we report the first case of a CNL patient positive for a de-novo germline CSF3R T618I ...

Nearly one in five people in the UK are believed to suffer from chronic inflammation – but there are ways to reduce it There’s an important distinction to be made between acute inflammation ...

In some countries, including the US, Scemblix is also approved in patients with Ph+ CML-CP with the T315I mutation. Scemblix is being studied across multiple treatment lines for Ph+ CML-CP, both as a ...

With the H5N1 bird flu virus spreading quickly across animals in the US, experts are on high alert for signs of human-to-human transmission. Such a jump could become far easier with just a single ...

A new study by biologists from the Scripps Research Institute shows that a bird flu virus is just a single mutation away from having human-ready receptors. If the H5N1 virus does make the switch ...

The data included results from all patients with KMT2A rearrangement (KMT2Ar) or NPM1 mutation (NPM1m) who had received at least one dose of enzomenib and who had not received a menin inhibitor ...